Exploiting immunotheraphy in Mycobacterium tuberculosis-infected mice: Sphingosine 1-phosphate treatment results in a protective or detrimental effect depending on the stage of infection

M. Sali, G. Delogu, E. Greco, S. Rocca, V. Colizzi, G. Fadda, Maurizio Fraziano

Research output: Contribution to journalArticle

Abstract

Sphingosine 1-phosphate (S1P) is a natural lysophospholipid able to enhance antimycobacterial innate immune response. In the present study, we address the possible therapeutic role of SIP administered during primary or acute infection in mice aerogenically infected with Mycobacterium tuberculosis (MTB). Results show that the administration of S1P during primary infection significantly reduces the presence of MTB-infected cells within pulmonary granulomas and mycobacterial burden in the lung and in the spleen. However, if S1P treatment was started during acute infection, a detrimental effect was observed in terms of pulmonary histopathotogy and mycobacterial burden in the lung and in the spleen. Taken together, these results show that S1P can exert a therapeutic effect as a treatment of primary infection only.

Original languageEnglish
Pages (from-to)175-181
Number of pages7
JournalInternational Journal of Immunopathology and Pharmacology
Volume22
Issue number1
Publication statusPublished - Jan 2009

Keywords

  • Acute disease
  • Immunotherapy
  • Mice
  • Primary infection
  • Tuberculosis

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Exploiting immunotheraphy in Mycobacterium tuberculosis-infected mice: Sphingosine 1-phosphate treatment results in a protective or detrimental effect depending on the stage of infection'. Together they form a unique fingerprint.

  • Cite this